Neurokinin-1 receptor inhibition promoted TP53 signaling and suppressed the transcription factor E2F2 in NB cells, and aprepitant (a neurokinin-1 receptor antagonist) reduced the tumor size in vivo [65]. Here, TACR1 is linked to neoplasm.